OZURDEX® (dexamethasone intravitreal implant): For the treatment of adult patients with visual impairment due to diabetic macular edema (DME) who are considered unsuitable for, or insufficiently responsive to, non-corticosteroid therapy or are pseudophakic.

**Contraindications:**
- Hypersensitivity to the active substance or to any of the excipients.
- Active or suspected ocular or periocular infection.
- Broad-spectrum antimicrobial drops daily for 3 days before and after each injection.

**Warnings/Precautions:**
- The intravitreal injection procedure should be carried out under controlled aseptic conditions as beyond 7 implants. Patients should be monitored following the injection to permit early treatment if an implant migration occurs.
- Posterior subcapsular cataracts, cataracts, including OZURDEX, may induce cataracts (including posterior subcapsular cataracts), and may result in secondary ocular infections. The rise in IOP is normalised with IOP lowering medications. Cataracts should be used cautiously in patients with a history of ocular herpes simplex virus and not be used in active ocular herpes simplex virus.
- Dislocation of the implant requires surgical intervention.
- Use of corticosteroids, including OZURDEX, may induce secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes. In vitro, OZURDEX is not recommended during pregnancy unless considered necessary. OZURDEX should be used with caution in patients taking anticoagulant or antiplatelet medicinal products.

**Adverse Effects:**
- Adverse event reports should be reported to your local regulatory authorities and your Allergan office.

References:
2. POM.

Date of preparation: September 2014

Please refer to local country Summary of Product Characteristics (SmPC).
Letters are only accepted if they directly concern spaced manuscript pages), including an abstract of max. 15 double-spaced manuscript pages. Letter to the Editor. New Technologies in Ophthalmology. Review. Original Paper. Types of Papers will be published at the end of the issue. The abstract is of utmost importance. It should contain the following information: purpose of the study, procedures, results, conclusions and message of the paper.

Conditions

All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. A cover letter with the name, address, and tele- phone and telefax numbers of the corresponding author must accompany each manuscript. This letter must include a statement that affirms that all authors concur with the submission. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Ophthalmologica and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflicts of Interest

Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the article.

Types of Papers

Editorial Original Paper Review New Technologies in Ophthalmology Letter to the Editor Euretina Lecture Reviews are either invited, or may be submitted for consideration. Invited reviews, if accepted, are not subject to page charges. The recommended length is 6 printed pages (approx. 15 double-spaced manuscript pages).

Mini Reviews should contain an easy-to-read literature overview on a specific topic. Papers should be either invited or may be submitted for consideration. Only concise articles of no more than 2 printed pages (approx. 6 double-spaced manuscript pages), including an abstract of max. 200 words and references, will be accepted. Please submit your mini review online.

Letter to the Editor

Letters are only accepted if they directly concern articles previously published in this journal and clinical subjects related to the matters discussed. The editor reserves the right to submit copies of such letters to the authors of the articles concerned prior to publication in order to permit them to respond in the same issue of the journal. Letters should have a maximum of one printed page (460–820 words, up to 8 references).

Arrangement

Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head. Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Each paper needs an abstract in English of not more than 150 words. The abstract is of utmost importance. It should contain the following information: purpose of the study, procedures, results, conclusions and message of the paper.

Footnotes: Avoid footnotes.

Tables and illustrations: Table and illustrations (both numbered in Arabic numerals) should be sent in separate files. Tables require a heading and figures a legend, also in a separate file. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm). Black and white half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi.

Color illustrations: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.00 per page.

References: In the text, identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples


(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum inter- leukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.


Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material

Supplementary material is directed to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, avi, .mpeg).

Author’s Choice

Karger’s Author’s Choice service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.Karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/author_choice.

NIH-Funded Research

The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy is available at http://publicaccess.nih.gov/policy.htm

Self-Archiving

Karger permits authors to archive their pre-prints (i.e. pre-refereed) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s Choice feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

Page Charges

There are no page charges for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a paper is equal to approx. 8 manuscript pages (including tables, illustrations and references).

Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

Reprints

Orders forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
Subscription Rates: Subscriptions run for a full calendar year. Prices are given per year.

Personal subscription:

<table>
<thead>
<tr>
<th>Country</th>
<th>Print Online</th>
<th>Print+Online combined</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHF</td>
<td>EUR</td>
<td>USD</td>
</tr>
<tr>
<td>1077.00</td>
<td>1173.00</td>
<td>1299.00</td>
</tr>
<tr>
<td>897.00</td>
<td>975.00</td>
<td>1195.00</td>
</tr>
<tr>
<td>1099.00</td>
<td>1297.00</td>
<td>1497.00</td>
</tr>
</tbody>
</table>

postage and handling:
- CHF 60.80 Europe, CHF 89.60 Overseas
- USD 51.20
- USD 83.20

Institutional subscription:

<table>
<thead>
<tr>
<th>Country</th>
<th>Print Online</th>
<th>Print+Online combined</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHF</td>
<td>EUR</td>
<td>USD</td>
</tr>
<tr>
<td>2153.00</td>
<td>2476.00</td>
<td>2700.00</td>
</tr>
<tr>
<td>1794.00</td>
<td>2063.00</td>
<td>2257.00</td>
</tr>
<tr>
<td>2197.00</td>
<td>2527.00</td>
<td>2757.00</td>
</tr>
</tbody>
</table>

postage and handling:
- CHF 76.00 Europe, CHF 112.00 Overseas
- USD 64.00
- USD 104.00

Discount subscription prices:
- Association for Research and Vision in Ophthalmology (ARVO)
- EURETINA
- and other related societies

Back Volumes and Single Issues: Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at service@karger.com.

Bibliographic Indices: This journal is regularly listed in bibliographic services, including Current Contents® and PubMed/MEDLINE.

Photocopying: This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for the personal or internal use of specific clients, provided that the stated fee is paid per copy directly to Copyright Clearance Center Inc.

Ophthalmologica is published 8 times a year. Volumes 231 and 232, each with 4 issues, appear in 2014.

Discount subscription prices:

- USA
  - S. Karger Publishers, Inc.
    - 26 West Avon Road
    - P.O. Box 529
    - Unionville, CT 06085
    - Toll free: +1 800 828 5479
    - e: service@karger.de
    - w: www.karger.de

- Japan
  - Karger Japan, Inc.
    - 23, rue du Départ, boîte 37
    - 75014 Paris
    - France
    - Toll free: +33 (0) 6 81 04 76 85
    - e: albertineluginbuhl@orange.fr
    - w: www.karger.de

- South East Asia, China and Taiwan
  - Karger Regional Office (Malaysia)
    - Level 28-03-03A, PJ Exchange
    - No. 16A, Persiaran Barat
    - 46050 Petaling Jaya
    - Selangor Darul Ehsan
    - Malaysia
    - Toll free: +60 3 7962 0158
    - e: service@karger.cn; r.chew@karger.cn

- Karger China
  - 51F Raffles City Centre
  - 268 Xi Zang Middle Road
  - Huang Pu District
  - Shanghai 200001
  - P.R. China
  - Toll free: +86 21 2312 7673
  - e: service@karger.cn; r.chew@karger.cn
  - w: www.karger.cn

- India, Bangladesh, Sri Lanka
  - Karger India
    - Plot No. 17, Yunaf Sarai Market
    - B.L. Glass Building, 2nd Floor
    - South Avenue Marg
    - New Delhi 110 016
    - India
    - Toll free: +91 11 46029 634
    - e: karger@snet.net
    - w: www.karger.de

- Japan
  - Karger Publishers
    - 26 West Avon Road
    - P.O. Box 529
    - Unionville, CT 06085
    - Toll free: +1 800 828 5479
    - e: service@karger.de
    - w: www.karger.de

- US
  - S. Karger Publishers, Inc.
    - 26 West Avon Road
    - P.O. Box 529
    - Unionville, CT 06085
    - Toll free: +1 800 828 5479
    - e: service@karger.de
    - w: www.karger.de

- Germany
  - S. Karger GmbH
    - Postfach
    - 79095 Freiburg
    - Deutschland
    - (Hausadresse: Wilhelmstrasse 20A, 79098 Freiburg)
    - t: +49 761 45 20 70
    - f: +49 761 45 20 714
    - e: information@karger.de
    - w: www.karger.de

- France
  - Enter & Read
    - Albertine Lugnibuhl
    - 23, rue du Départ, boîte 37
    - 75014 Paris
    - France
    - Toll free: +33 (0) 6 81 04 76 85
    - e: albertineluginbuhl@orange.fr
    - w: www.karger.de

- Karger Japan
  - Karger Japan, Inc.
    - Shiba Daimon Asahi Bldg., 2F
    - 1-2-23 Shiba Daimon
    - Minato-ku
    - Tokyo 105-0012
    - Japan
    - Toll free: +86 21 2312 7673
    - e: service@karger.cn
    - w: www.karger.de

- Karger China
  - 51F Raffles City Centre
  - 268 Xi Zang Middle Road
  - Huang Pu District
  - Shanghai 200001
  - P.R. China
  - Toll free: +86 21 2312 7673
  - e: service@karger.cn
  - r.chew@karger.cn
  - w: www.karger.cn
SEE YOU IN VIENNA!
www.soe2015.org

Register Now!
Visit www.soe2015.org to register
Contents

See the journal website for contents
A noninvasive, reliable and patient-friendly diagnostic technique

Optical Coherence Tomography

Editors
Gabriel Coscas
Anat Loewenstein
Francesco Bandello

Because of its many advantages optical coherence tomography (OCT) has revolutionized the way in which retinal diseases are screened and managed and how treatments are monitored. In this volume the latest developments and findings are presented by experts in their respective fields. After a short introduction covering the available equipment and the basic techniques, the imaging features of various pathological findings in retinal diseases are presented. The topics cover the outer layers including new modalities for choroid imaging, out-layer diseases such as the various types of macular degeneration, retinal diseases such as diabetic retinopathy and vascular occlusion, and retina and vitreous interface pathologies. The final chapters are dedicated to the practicality of using OCT for the pre- and postsurgical evaluation of the posterior segment and for the differential diagnosis of vitreoretinal diseases as well as in the management of patients with retinal and neuro-ophthalmological diseases. Making the essentials of the recently held ESASO course on OCT available in one volume, this publication is a must-read for experienced as well as trainee ophthalmologists who need to use OCT in their daily practice.

Contents
Preface: Coscas, G.; Loewenstein, A.
• Evolution of Optical Coherence Tomography Technology
  Comparison of Commercially Available Instruments: Pierro, L.; Gagliardi, M.
• Optical Coherence Tomography Pathologic Findings in the Vitreoretinal and Macular Interface: Goldenberg, D.; Schwartz, R.; Loewenstein, A.
• Optical Coherence Tomography in the Inner Retinal Layers: Giraud, J.M.; El Chehab, H.; Francoz, M.; Fenolland, J.R.; Delbarre, M.; May, F.; Renard, J.P.
• Optical Coherence Tomography of the Outer Retinal Layers: Koh, A.
• Optical Coherence Tomography Findings in the Choroid: Coscas, G.; Coscas, F.
• Pre- and Postsurgical Evaluation of the Retina by Optical Coherence Tomography: Pellegrini, M.; Bottoni, F.; Cereda, M.G.; Staurenghi, G.
• Optical Coherence Tomography in the Diagnosis of Challenging Macular Disorders: Querques, G.; Borrelli, E.; Georges, A.; Souied, E.H.
• Optical Coherence Tomography in the Management of Diabetic Macular Edema: Erginay, A.; Massin, P.
• Swept Source Optical Coherence Tomography versus Enhanced Depth Imaging-Spectral Domain Optical Coherence Tomography in Age-Related Macular Degeneration: Coscas, F.; Coscas, G.
• ‘En Face’ Optical Coherence Tomography with Enhanced Depth Imaging of Different Patterns of the Choroidal Neovascular Network in Age-Related Macular Degeneration: Coscas, G.; Coscas, F.
• ‘En Face’ Optical Coherence Tomography Scan Applications in the Inner Retina: Lumbrero, B.; Rispoli, M.; Le Rouic, J.F.; Savastano, M.C.
• Optical Coherence Tomography Findings in Acute Macular Neuroretinopathy: Battaglia Parodi, M.; Iacono, P.; Panico, D.; Cascavilla, M.L.; Bolognesi, G.; Bandello, F.
• Optical Coherence Tomography in Myopic Choroidal Neovascularization: Battaglia Parodi, M.; Iacono, P.; Bolognesi, G.; Bandello, F.
• Choroidal Changes in Patients with Raynaud’s Phenomenon: Secondary to a Connective Tissue Disease: Study of Vascular Eye Involvement in Patients Affected by Raynaud’s Phenomenon with in vivo Noninvasive EDI-OCT: Pierro, L.; Del Turco, C.; Misericocchi, E.; Ingegnoli, F.

The easiest way to order: www.karger.com/esaso

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com, f +41 61 306 12 34
www.karger.com
A comprehensive source of authoritative information on ocular and adnexal radiation therapy

Ophthalmic Radiation Therapy
Techniques and Applications

Editors:
Arun D. Singh
David E. Pelayes
Stefan Seregard
Roger Macklis

This publication, a conjoint effort by ocular oncologists and radiation oncologists, comprises ten chapters covering basic and advanced radiation therapy techniques followed by specific indications by location (uveal, retinal, orbital tumors, eyelid and conjunctival tumors) and complications of radiation therapy. A chapter on investigational use of radiation therapy for age-related macular degeneration is also included. The contributions are illustrated by photographs, imaging studies, and detailed treatment plans to clearly convey the fundamental concepts. Additional tables, flow diagrams, graphs or charts support the understanding of the subject.

To ocular oncologists, radiation physicists, radiation therapists, and radiation oncologists this volume is a comprehensive source of authoritative information on the subject of ocular and adnexal radiation therapy.

Contents
Foreword: Lommatzsch, P.K.
• Teletherapy: Advanced Techniques: Stockholm, A.; Balagamwala, E.H.; Singh, A.D.; Macklis, R.
• Brachytherapy: Marwaha, G.; Macklis, R.; Singh, A.D.; Wilkinson, A.
• Radiation Therapy: Uveal Tumors: Seregard, S.; Pelayes, D.E.; Singh, A.D.
• Radiation Therapy: Retinal Tumors: Sethi, R.V.; MacDonald, S.M.; Kim, D.Y.; Mukai, S.
• Radiation Therapy: Age-Related Macular Degeneration: Medina Mendez, C.A.; Ehlers, J.P.
• Radiation Therapy: Conjunctival and Eyelid Tumors: Aronow, M.E.; Singh, A.D.
• Radiation Therapy: Orbital Tumors: Marwaha, G.; Macklis, R.; Singh, A.D.
• Radiation Therapy: Anterior Segment Complications: Medina Mendez, C.A.; Singh, A.D.

Subject Index

The easiest way to order: www.karger.com/deoph

Dear Librarian
I have reviewed this publication and would like to recommend it for our library.
Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

KARGER
Ophthalmic Research features original papers, reviews and short communications reporting on translational and clinical studies. Authors from throughout the world cover topics on glaucoma, cataract and refractive surgery, retina, uveitis, and other fields in connection with physical, physiologic, pharmacological, biochemical and molecular biological aspects of ophthalmology. This journal provides a record of international clinical research for both researchers and clinicians in ophthalmology.

The journal further offers, at a reasonable price, the possibility of publishing dedicated supplements and abstracts of conferences and symposia. Please consult the managing editor for this.

Ophthalmic Research

Vision in focus

Ophthalmic Research specialises in comprehensive reviews, early reports of findings and abstracts of conferences and symposia. The journal acts as a forum for researchers and clinicians in the field of ophthalmology. It provides a record of international clinical research for both researchers and clinicians in ophthalmology.

Editor
José Cunha-Vaz, Coimbra

Associate Editors
Age-Related Macular Degeneration
José-Alain Sahel, Paris

Diabetic Retinopathy and Retinal Vascular Diseases
Reinier O. Schlingemann, Amsterdam

Genetics
Bart Leroy, Ghent

Glucoma
Ingeborg Stalmans, Leuven

Immunology and Infectious Diseases
Dorairajan Balasubramanian, Hyderabad

Imaging
Tunde Peto, London

Oncology and Pathology
Eduardo Miden, Padua

Surgery
Yuichiro Ogura, Nagoya

Neuro-Ophthalmology and Visual Function
Birgit Lorenz, Giessen

Anterior Segment
Marie-José Tassignon, Antwerp

EVIRC.net
Cecilia Martinho, Coimbra

Epidemiology
Cécile Delcourt, Bordeaux

Educational – ESASO
Bruno Falcomata, Lugano
Maurizio Battaglia Parodi, Milan

New Editor
José Cunha-Vaz, Coimbra

Impact Factor: 1.376

Selected contributions
• Expression of CREB in Primary Pterygium and Correlation with Cyclin D1, ki-67, MMP7, p53, Survivin and Vimentin: Nubile, M.; Curcio, C.; Lanzini, M.; Callelo, R.; Iezzi, M.; Mastropasqua, A.; Di Nicola, M.; Mastropasqua, L. (Chieti/Pescara)

• Progenitor Cells for Ocular Surface Regenerative Therapy: Casaroli-Marano, R.P.; Nieto-Nicolau, N.; Martinez-Conesa, E.M. (Barcelona)

• Comparative Study of the Effects of Recombinant Human Epidermal Growth Factor and Basic Fibroblast Growth Factor on Corneal Epithelial Wound Healing and Neovascularization in vivo and in vitro: Yan, L.; Wu, W.; Wang, Z.; Li, C.; Lu, X.; Duan, H.; Zhou, J.; Wang, X.; Wan, P.; Song, Y. (Guangzhou); Tang, J.; Han, Y. (Shenzhen)

• The Effect of Chronic Smoking on the Pupil and Photostress Recovery Time: Sobaci, G.; Erdem, Ü.; Gundogdu, F.C.; Musayev, S. (Itlik)

• Intravitreal Bevacizumab Injection for Iris Neovascularization after Vitrectomy for Proliferative Diabetic Retinopathy: Salman, A.G. (Cairo)


• Ocular Surface Temperature Gradient Is Increased in Eyes with Bacterial Corneal Ulcers: Klaman, M.K.; Maier, A.-K.B.; Gonnermann, J.; Klein, J.P.; Bertellmann, E.; Pleyer, U. (Berlin)

• High Vitreous Concentration of IL-6 and IL-8, but Not of Adhesion Molecules in Relation to Plasma Concentrations in Proliferative Diabetic Retinopathy: Koskela, U.E.; Kuusisto, S.M.; Niissinen, A.E.; Savolainen, M.J.; Liinamaa, M.J. (Oulu)

More information at www.karger.com/ore

Ophthalmic Research

Journal for Translational and Clinical Research

Founded: 1970
Category: Clinical and Basic Research
Field of Interest: Dermatology

Listed in bibliographic services, including Current Contents®/Life Sciences, PubMed/MEDLINE, Biological Abstracts

2015: Volume 53, 54
4 issues per volume
Language: English
ISSN 0030–3747
e-ISSN 1423–0259

KF15079_cmyk
The Effect of Intensive Education on Concordance with the Age-Related Eye Disease Study (AREDS) Recommendations in a Tertiary Referral Practice
Weaver, T.R.E. (Sydney, N.S.W./Gold Coast, Qld.); Beaumont, P.E. (Sydney, N.S.W.)

Ranibizumab plus Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: 12 Months of Retreatment and Vision Outcomes from a Randomized Study
Hatz, K. (Binningen/Liestal/Basel); Schneider, U.; Henrich, P.B.; Braun, B. (Basel); Sacu, S. (Vienna); Prünte, C. (Binningen/Liestal/Basel/Vienna)

Intravitreal Ranibizumab for Predominantly Hemorrhagic Choroidal Neovascularization in Age-Related Macular Degeneration
Lazzeri, S. (Rome/Pisa); Figus, M.; Sartini, M.S. (Pisa); Scarinci, F. (Rome); Casini, G.; Guidi, G. (Pisa); Capo, G.; Cacciamani, A. (Rome); Fasanello, V.; Agnifili, L. (Chieti); Piaggi, P. (Pisa); Varano, M.; Ripandelli, G. (Rome); Nardi, M. (Pisa); Parravano, M. (Rome)

Stereotactic Radiotherapy for Polypoidal Choroidal Vasculopathy: A Pilot Study
Introini, U.; Casalino, G.; Triolo, G. (Milan); O'Shaughnessy, D.; Shusterman, E.M. (Newark, Calif.); Chakravarthy, U. (Belfast); Slakter, J.S. (New York, N.Y.); Bandello, F. (Milan)

RaScAL: A Pilot Study to Assess the Efficacy, Durability, and Safety of a Single Intervention with Ranibizumab plus Peripheral Laser for Diabetic Macular Edema Associated with Peripheral Nonperfusion on Ultrasound-Field Fluorescein Angiography

Screening for Diabetic Retinopathy in the Central Region of Portugal. Added Value of Automated ‘Disease/No Disease’ Grading
Ribeiro, L.; Oliveira, C.M.; Neves, C.; Ramos, J.D.; Ferreira, H.; Cunha-Vaz, J. (Coimbra)

23-Gauge versus 25-Gauge Vitrectomy for Proliferative Diabetic Retinopathy: A Comparison of Surgical Outcomes
Guthrie, G.; Magill, H. (London); Steel, D.H.W. (Sunderland/Newcastle upon Tyne)

Comment on the Paper by Kuniyoshi et al. Entitled ‘Multifocal Electroretinograms in Stargardt’s Disease/Fundus Flavimaculatus’
Gundogan, F.C. (Ankara); Taş, A. ( Ağrı); Yolcu, U. (Kars); Ilhan, A. (Erzurum)

Macular Electroretinogram in Stargardt’s Disease/Fundus Flavimaculatus
Kuniyoshi, K. (Boston, Mass./Osaka); Terasaki, H. (Boston, Mass./Nagoya); Arai, M. (Boston, Mass./Fukuoka); Hirose, T. (Boston, Mass./Brookline, Mass.)

Comment on the Paper by Douvali et al. Entitled ‘Effect of Macular Ischemia on Intravitreal Ranibizumab Treatment for Diabetic Macular Edema’
Ilhan, A. (Erzurum); Tas, A. ( Ağrı); Yolcu, U. (Kars); Gundogan, F.C. (Ankara)

Reply to the Comment by Ilhan et al. on Our Paper Entitled ‘Effect of Macular Ischemia on Intravitreal Ranibizumab Treatment for Diabetic Macular Edema’
Chatziralli, I.; Douvali, M.; Theodossiadis, P.; Rouvas, A.A. (Athens)

Comment on the Article by Dutra Medeiros et al. Entitled ‘Dexamethasone Intravitreal Implant for Treatment of Patients with Persistent Diabetic Macular Edema’
Arikan Yorgun, M.; Toklu, Y. (Ankara)

Permission to use this illustration was kindly granted by Andreas Knauf.